Compare · BHSE vs BNTX
BHSE vs BNTX
Side-by-side comparison of Bull Horn Holdings Corp. (BHSE) and BioNTech SE (BNTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BHSE and BNTX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $26.50B, about 282.4x BHSE ($93.8M).
- BNTX has hit the wire 5 times in the past 4 weeks while BHSE has been quiet.
- BNTX has more recent analyst coverage (25 ratings vs 0 for BHSE).
- Company
- Bull Horn Holdings Corp.
- BioNTech SE
- Price
- $12.50+50.42%
- $105.40-0.14%
- Market cap
- $93.8M
- $26.50B
- 1M return
- -
- +18.61%
- 1Y return
- -
- +1.32%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2019
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 25
Bull Horn Holdings Corp.
Bull Horn Holdings Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the sports, entertainment, and brands sectors. The company was incorporated in 2018 and is based in Miami Beach, Florida.
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Latest BHSE
- SEC Form SC 13G filed by Bull Horn Holdings Corp.
- SEC Form 424B3 filed by Bull Horn Holdings Corp.
- SEC Form 424B3 filed by Bull Horn Holdings Corp.
- Bull Horn Holdings Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events
- Cogley Brian bought $3,350 worth of shares (5,000 units at $0.67), increasing direct ownership by 20% to 30,000 units (SEC Form 4)
- New insider Cogley Brian claimed ownership of 30,000 shares (SEC Form 3)
- Desilva Tara bought $1,305 worth of shares (2,266 units at $0.58), increasing direct ownership by 8% to 32,266 units (SEC Form 4)
- Yerace Daniel Alexander bought $7,486 worth of shares (10,850 units at $0.69), increasing direct ownership by 1% to 1,071,455 units (SEC Form 4)
- Salkind Gene bought $8,004 worth of shares (11,600 units at $0.69), increasing direct ownership by 4% to 284,056 units (SEC Form 4)
- Mehalick David bought $16,747 worth of shares (25,054 units at $0.67), increasing direct ownership by 0.91% to 2,782,615 units (SEC Form 4)
Latest BNTX
- Chief Operating Officer Poetting Sierk sold $5,527,960 worth of Ordinary Shares (50,000 units at $110.56) (SEC Form 4)
- BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
- Amendment: SEC Form 3 filed by new insider Sahin Ugur
- SEC Form 6-K filed by BioNTech SE
- BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
- SEC Form 6-K filed by BioNTech SE
- Amendment: SEC Form 20-F/A filed by BioNTech SE
- SEC Form 3 filed by new insider Blackwood Nicola Claire
- SEC Form 3 filed by new insider Morawietz Anja
- SEC Form 3 filed by new insider Staudigl Rudolf